+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Long-Acting Insulin Analogue Market - Global Forecast 2026-2032- Product Image
Long-Acting Insulin Analogue Market - Global Forecast 2026-2032- Product Image
Sale

Long-Acting Insulin Analogue Market - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6159591
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Long-Acting Insulin Analogues: Executive Summary

Long-acting insulin analogues are basal insulin therapies designed to provide relatively sustained glucose-lowering activity and support consistent daily diabetes management. Their clinical role is shaped by treatment guidelines, patient adherence, injection frequency, affordability, reimbursement, diabetes prevalence, and access to diagnosis and monitoring. Market development therefore depends on both therapeutic performance and health-system capacity.

Treatment Access and Delivery Models Are Reshaping Basal Insulin Use

The landscape is shifting toward more individualized basal-insulin selection, simplified dosing, and care models that emphasize persistence and hypoglycemia risk management. Increasing use of connected glucose monitoring, diabetes education, pharmacy-led support, and remote consultations is changing how treatment is initiated and adjusted. At the same time, procurement policies, biosimilar adoption, tendering, cold-chain requirements, and efforts to expand primary-care access continue to influence availability across health systems.

Artificial Intelligence Strengthens Personalization, Monitoring, and Operations

Artificial intelligence is contributing to diabetes care through glucose-pattern analysis, decision support, risk stratification, and workflow automation. When integrated with continuous or intermittently scanned glucose monitoring, analytical tools can help clinicians identify nocturnal hypoglycemia, persistent fasting hyperglycemia, and adherence barriers. AI can also support demand planning and patient engagement, although clinical validation, explainability, cybersecurity, data quality, and equitable access remain essential safeguards.

Regional Differences Reflect Affordability, Infrastructure, and Care Capacity

North America is characterized by broad access to advanced diabetes technologies alongside substantial affordability and coverage variation. Europe benefits from established clinical guidance and organized reimbursement, but access differs across national systems. Asia-Pacific combines expanding diabetes-care capacity with pronounced differences between urban and rural settings. Latin America continues to face procurement, affordability, and continuity-of-care challenges. The Middle East is investing in chronic-disease programs and digital health while addressing rising care demand. Africa’s priorities include earlier diagnosis, reliable insulin supply, trained personnel, and stronger primary-care integration.

Economic and Political Groupings Reveal Uneven Policy and Procurement Conditions

ASEAN markets show varied reimbursement systems, healthcare infrastructure, and diabetes-program maturity, making regional coordination valuable but complex. BRICS members span highly different manufacturing capabilities, regulatory pathways, and public-procurement models. European Union countries share regulatory foundations while retaining national reimbursement decisions. G7 systems generally have sophisticated clinical infrastructure but face affordability, aging-population, and health-workforce pressures. GCC countries are strengthening chronic-disease prevention and specialist services, while NATO members remain diverse in healthcare financing and resilience priorities. Across all groups, reliable supply and equitable access remain central concerns.

Country-Level Priorities Range from Technology Integration to Basic Access

Australia emphasizes coordinated diabetes care, reimbursement design, and remote support across dispersed populations. Brazil and Mexico continue to address affordability, public procurement, and regional access. Canada faces geographic variation and coverage differences, while the United States combines advanced monitoring with significant cost and insurance complexity. China and India are expanding diabetes diagnosis and treatment capacity across highly diverse populations. Japan, South Korea, Singapore, and other advanced Asian systems prioritize aging-related care, adherence, and digital integration. France, Germany, Italy, Spain, and the United Kingdom rely on structured healthcare systems while managing budget discipline and outcome-based care. Russia’s priorities include supply continuity, domestic capability, and access across a geographically extensive system.

Industry Leaders Should Prioritize Access, Evidence, and Integrated Patient Support

Leaders should align product and service strategies with local reimbursement rules, procurement requirements, and clinical guidelines rather than assuming a uniform global pathway. Strengthening supply-chain resilience, temperature-controlled distribution, and quality systems can improve continuity of therapy. Patient-support programs should address injection technique, titration education, persistence, and hypoglycemia awareness. Partnerships with providers and payers can generate real-world evidence on adherence and outcomes, while responsible AI deployment should include clinical oversight, transparent validation, privacy protection, and monitoring for unequal performance.

Research Methodology: Evidence-Based Synthesis of Clinical and Health-System Drivers

This executive summary uses the defined long-acting insulin analogue category and synthesizes established evidence themes from clinical practice, diabetes-care policy, healthcare access, reimbursement, technology adoption, and regional health-system conditions. The analysis is structured across the specified regions, economic and political groups, and countries. It excludes market estimates, market sizing, market shares, forecasts, and company-specific claims, and treats geographic comparisons as qualitative assessments of documented care environments and adoption drivers.

Conclusion: Sustainable Progress Depends on Reliable Access and Personalized Care

Long-acting insulin analogues remain an important component of basal diabetes treatment, but their impact depends on more than pharmacology. Durable progress requires dependable supply, affordable coverage, trained care teams, patient-centered education, appropriate monitoring, and evidence-based use of digital and AI tools. Strategies that combine clinical value with health-system practicality are best positioned to improve continuity, safety, and equitable diabetes management across diverse settings.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Long-Acting Insulin Analogue Market, by Type
7.1. Introduction
7.2. Insulin Degludec
7.3. Insulin Detemir
7.4. Insulin Glargine
7.5. Insulin Icodec
8. Long-Acting Insulin Analogue Market, by Delivery
8.1. Introduction
8.2. Insulin Pump
8.3. Prefilled Pen
8.4. Vial And Syringe
9. Long-Acting Insulin Analogue Market, by Application
9.1. Introduction
9.2. Gestational Diabetes
9.3. Type 1 Diabetes
9.4. Type 2 Diabetes
10. Long-Acting Insulin Analogue Market, by End User
10.1. Introduction
10.2. Clinic
10.3. Home Care Setting
10.4. Hospital
10.5. Specialty Center
11. Long-Acting Insulin Analogue Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Long-Acting Insulin Analogue Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Long-Acting Insulin Analogue Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. AstraZeneca PLC
15.2. Biocon Limited
15.3. Boehringer Ingelheim International GmbH
15.4. Eli Lilly and Company
15.5. Gan & Lee Pharmaceuticals
15.6. MannKind Corporation
15.7. Merck & Co., Inc.
15.8. Novo Nordisk A/S
15.9. Pfizer Inc.
15.10. Samsung Bioepis Co., Ltd.
15.11. Sanofi S.A.
15.12. Teva Pharmaceutical Industries
15.13. Tonghua Dongbao Pharmaceutical
15.14. Viatris Inc.
15.15. Wockhardt Ltd.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Long-Acting Insulin Analogue Market, Years Considered for the Study
FIGURE 2. Global Long-Acting Insulin Analogue Market, Research Design
FIGURE 3. Global Long-Acting Insulin Analogue Market, Research Framework
FIGURE 4. Global Long-Acting Insulin Analogue Market, Data Triangulation
FIGURE 5. Global Long-Acting Insulin Analogue Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Long-Acting Insulin Analogue Market Size, by Type, 2025 vs 2032 (%)
FIGURE 7. Global Long-Acting Insulin Analogue Market Size, by Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Long-Acting Insulin Analogue Market Size, by Delivery, 2025 vs 2032 (%)
FIGURE 9. Global Long-Acting Insulin Analogue Market Size, by Delivery, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Long-Acting Insulin Analogue Market Size, by Application, 2025 vs 2032 (%)
FIGURE 11. Global Long-Acting Insulin Analogue Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Long-Acting Insulin Analogue Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Long-Acting Insulin Analogue Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Long-Acting Insulin Analogue Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Long-Acting Insulin Analogue Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Long-Acting Insulin Analogue Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Long-Acting Insulin Analogue Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Long-Acting Insulin Analogue Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Long-Acting Insulin Analogue Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Long-Acting Insulin Analogue Market Segmentation & Coverage
TABLE 2. Global Long-Acting Insulin Analogue Market Size, 2017-2032 (USD Million)
TABLE 3. Global Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 4. Global Insulin Degludec Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Insulin Degludec Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Insulin Degludec Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Insulin Detemir Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Insulin Detemir Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Insulin Detemir Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Insulin Glargine Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Insulin Glargine Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Insulin Glargine Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Insulin Icodec Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Insulin Icodec Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Insulin Icodec Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 17. Global Insulin Pump Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Insulin Pump Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Insulin Pump Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Prefilled Pen Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Prefilled Pen Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Prefilled Pen Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Vial And Syringe Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Vial And Syringe Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Vial And Syringe Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 27. Global Gestational Diabetes Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Gestational Diabetes Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Gestational Diabetes Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Type 1 Diabetes Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Type 1 Diabetes Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Type 1 Diabetes Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Type 2 Diabetes Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Type 2 Diabetes Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Type 2 Diabetes Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 37. Global Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Home Care Setting Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Home Care Setting Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Home Care Setting Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Specialty Center Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Specialty Center Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Specialty Center Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Long-Acting Insulin Analogue Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Asia-Pacific Long-Acting Insulin Analogue Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Asia-Pacific Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 52. Asia-Pacific Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 53. Asia-Pacific Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 54. Asia-Pacific Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 55. North America Long-Acting Insulin Analogue Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. North America Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 57. North America Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 58. North America Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 59. North America Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 60. Latin America Long-Acting Insulin Analogue Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Latin America Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 62. Latin America Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 63. Latin America Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 64. Latin America Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 65. Europe Long-Acting Insulin Analogue Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Europe Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 67. Europe Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 68. Europe Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 69. Europe Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 70. Middle East Long-Acting Insulin Analogue Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Middle East Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 72. Middle East Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 73. Middle East Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 74. Middle East Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 75. Africa Long-Acting Insulin Analogue Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Africa Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 77. Africa Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 78. Africa Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 79. Africa Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 80. Global Long-Acting Insulin Analogue Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. ASEAN Long-Acting Insulin Analogue Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. ASEAN Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 83. ASEAN Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 84. ASEAN Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 85. ASEAN Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 86. GCC Long-Acting Insulin Analogue Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. GCC Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 88. GCC Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 89. GCC Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 90. GCC Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 91. European Union Long-Acting Insulin Analogue Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. European Union Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 93. European Union Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 94. European Union Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 95. European Union Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 96. BRICS Long-Acting Insulin Analogue Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. BRICS Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 98. BRICS Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 99. BRICS Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 100. BRICS Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 101. G7 Long-Acting Insulin Analogue Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. G7 Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 103. G7 Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 104. G7 Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 105. G7 Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 106. NATO Long-Acting Insulin Analogue Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. NATO Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 108. NATO Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 109. NATO Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 110. NATO Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 111. Global Long-Acting Insulin Analogue Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. United States Long-Acting Insulin Analogue Market Size, 2017-2032 (USD Million)
TABLE 113. United States Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 114. United States Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 115. United States Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 116. United States Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 117. Canada Long-Acting Insulin Analogue Market Size, 2017-2032 (USD Million)
TABLE 118. Canada Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 119. Canada Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 120. Canada Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 121. Canada Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 122. Mexico Long-Acting Insulin Analogue Market Size, 2017-2032 (USD Million)
TABLE 123. Mexico Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 124. Mexico Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 125. Mexico Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 126. Mexico Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 127. Brazil Long-Acting Insulin Analogue Market Size, 2017-2032 (USD Million)
TABLE 128. Brazil Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 129. Brazil Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 130. Brazil Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 131. Brazil Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 132. United Kingdom Long-Acting Insulin Analogue Market Size, 2017-2032 (USD Million)
TABLE 133. United Kingdom Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 134. United Kingdom Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 135. United Kingdom Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 136. United Kingdom Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 137. Germany Long-Acting Insulin Analogue Market Size, 2017-2032 (USD Million)
TABLE 138. Germany Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 139. Germany Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 140. Germany Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 141. Germany Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 142. France Long-Acting Insulin Analogue Market Size, 2017-2032 (USD Million)
TABLE 143. France Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 144. France Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 145. France Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 146. France Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 147. Russia Long-Acting Insulin Analogue Market Size, 2017-2032 (USD Million)
TABLE 148. Russia Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 149. Russia Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 150. Russia Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 151. Russia Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 152. Italy Long-Acting Insulin Analogue Market Size, 2017-2032 (USD Million)
TABLE 153. Italy Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 154. Italy Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 155. Italy Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 156. Italy Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 157. Spain Long-Acting Insulin Analogue Market Size, 2017-2032 (USD Million)
TABLE 158. Spain Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 159. Spain Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 160. Spain Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 161. Spain Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 162. China Long-Acting Insulin Analogue Market Size, 2017-2032 (USD Million)
TABLE 163. China Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 164. China Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 165. China Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 166. China Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 167. India Long-Acting Insulin Analogue Market Size, 2017-2032 (USD Million)
TABLE 168. India Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 169. India Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 170. India Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 171. India Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 172. Japan Long-Acting Insulin Analogue Market Size, 2017-2032 (USD Million)
TABLE 173. Japan Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 174. Japan Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 175. Japan Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 176. Japan Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 177. Australia Long-Acting Insulin Analogue Market Size, 2017-2032 (USD Million)
TABLE 178. Australia Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 179. Australia Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 180. Australia Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 181. Australia Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 182. South Korea Long-Acting Insulin Analogue Market Size, 2017-2032 (USD Million)
TABLE 183. South Korea Long-Acting Insulin Analogue Market Size, by Type, 2017-2032 (USD Million)
TABLE 184. South Korea Long-Acting Insulin Analogue Market Size, by Delivery, 2017-2032 (USD Million)
TABLE 185. South Korea Long-Acting Insulin Analogue Market Size, by Application, 2017-2032 (USD Million)
TABLE 186. South Korea Long-Acting Insulin Analogue Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. Global Long-Acting Insulin Analogue Market Share, by Key Player, 2025
TABLE 188. Global Long-Acting Insulin Analogue Market, Key Experts

Companies Mentioned

  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • Gan & Lee Pharmaceuticals
  • MannKind Corporation
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries
  • Tonghua Dongbao Pharmaceutical
  • Viatris Inc.
  • Wockhardt Ltd.

Related Topics

Related Reports

Basal Insulin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Basal Insulin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 180 Pages
  • Global
From
Diabetes Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Diabetes Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 160 Pages
  • Global
From
Adult-Onset Growth Hormone Deficiency - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Adult-Onset Growth Hormone Deficiency - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Short-Acting Insulin Market Report 2026 - Product Image

Short-Acting Insulin Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Long-acting Somatostatin Analogues Market - Global Forecast 2026-2032 - Product Image

Long-acting Somatostatin Analogues Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.